H.C. Wainwright raised the firm's price target on Ocular Therapeutix to $25 from $21 and keeps a Buy rating on the shares after the company discussed the outcome of its Type C meeting with the FDA during yesterday's investor day meeting. The updates suggest rapid market adoption and broad utilization, says the analyst, who has increased the firm's peak annual sales estimate and view of the probability of approval for Axpaxli following the meeting.
